The European Medicines Agency just announced yet another extension for the testing of Nitrosamines contamination.

The Step 1 risk evaluation for products containing chemically synthesised APIs should now be concluded and reported by 31st March 2021, and for those containing biological APIs, by 1st July 2021.

As per the previous guidance, all MAHs should inform the concerned Competent Authorities within their own country of the outcome of their risk evaluation using the dedicated portal where it exists, or via the dedicated templates available on the EMA website.

Furthermore, the Step 2 confirmatory testing for products containing chemically synthesised APIs are expected to be finalized at the latest by 26th September 2022 and for products containing biological APIs, by 1st July 2023.

The extension certainly relieves a little pressure on the pharma industry, but there is no guarantee of further extensions, so it’s advisable to act now.

Visit our Nitrosamines overview page to find out more, and discover why QUINTA-ANALYTICA have become european leaders in the field of nitros detection.

Additional News

  • 18 March 2024

    News from our newly opened clinic in Ostrava

    Our new Clinic in Ostrava (CZ) is gaining momentum step by step; therefore, we have some interesting news for you from the center of the action.

  • 19 December 2023

    Happy new year 2024

    As we bid farewell to 2023, it's time to express our deepest gratitude for the collaboration.

  • 4 December 2023

    Our new clinical unit in Ostrava comes to life

    It's a great pleasure to announce that after two years of hard work, the brand-new clinical unit in Ostrava with 36-beds capacity has been opened.